Panion acquires access to dog study

Panion has made an agreement with Copenhagen University about transfer and use of technical data from a study in dogs.

The study is conducted by well-reputed researchers and is very relevant for Panion’s development of our gene therapy product for dogs with epilepsy. The study is not yet published by the researchers, but Panion may use the data in the contact with FDA and other authorities to speed up the development process from the day the agreement is signed.

“We are very pleased with the agreement, and we expect that this will ease our way to the next trial for our innovative product and to the market” says Anja Holm,
CEO of Panion Animal Health.

Anja E. H. Holm, SEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

This press release contains information which Panion Animal Health AB is obliged to publish according to the EU market abuse regulation (MAR). This information was submitted by Panion’s CEO, Anja E. H. Holm, for publication on August 14 2017.

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.